Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2013 6
2014 2
2015 4
2018 2
2020 1
2021 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study.
Rotem O, Peretz I, Leviov M, Kuchuk I, Itay A, Tokar M, Paluch-Shimon S, Maimon O, Yerushalmi R, Drumea K, Evron E, Sonnenblick A, Gal-Yam E, Goldvaser H, Samih Y, Merose R, Bareket-Samish A, Soussan-Gutman L, Stemmer SM. Rotem O, et al. Among authors: kuchuk i. NPJ Breast Cancer. 2023 Jun 2;9(1):49. doi: 10.1038/s41523-023-00549-8. NPJ Breast Cancer. 2023. PMID: 37268607 Free PMC article.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
Reinhorn D, Kuchuk I, Shochat T, Nisenbaum B, Sulkes A, Hendler D, Rotem O, Tsoref D, Olitzky O, Goldvaser H, Sarfaty M, Neiman V, Prus J, Gottfried M, Yust-Katz S, Yerushalmi R. Reinhorn D, et al. Among authors: kuchuk i. Breast Cancer Res Treat. 2021 Jul;188(2):379-387. doi: 10.1007/s10549-021-06198-4. Epub 2021 Mar 27. Breast Cancer Res Treat. 2021. PMID: 33772709
Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2-negative breast cancer patients in Israel: A registry analysis.
Bar-Sela G, Samih Y, Yerushalmi R, Leviov M, Efrat Ben-Baruch N, Kuchuk I, Tokar M, Peretz-Yablonski T, Sonnenblick A, Soussan-Gutman L, Bareket-Samish A, Fried G, Paluch-Shimon S, Kaufman B, Hammerman A, Liebermann N, Stemmer SM. Bar-Sela G, et al. Among authors: kuchuk i. Breast J. 2020 Oct;26(10):2096-2098. doi: 10.1111/tbj.13870. Epub 2020 May 18. Breast J. 2020. PMID: 32419268 No abstract available.
Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Sella T, Gal Yam EN, Levanon K, Rotenberg TS, Gadot M, Kuchuk I, Molho RB, Itai A, Modiano TM, Gold R, Kaufman B, Shimon SP. Sella T, et al. Among authors: kuchuk i. Breast. 2018 Aug;40:141-146. doi: 10.1016/j.breast.2018.05.007. Epub 2018 May 22. Breast. 2018. PMID: 29800932
21 results